RecruitingNCT06949670

Alpha-Synuclein PET/CT in Various α-Syn-Related Disease

Sponsor

Tianjin Medical University

Enrollment

500 participants

Start Date

Apr 1, 2025

Study Type

OBSERVATIONAL

Conditions

Parkinson Disease Alpha Synuclein Pathology Alpha-Synuclein

Summary

To evaluate the potential usefulness of 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various α-Syn-related disease patients.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is using a special imaging scan (called alpha-synuclein PET/CT) to detect a protein called alpha-synuclein in the brains and bodies of people with Parkinson's disease and related conditions. The goal is to improve how these diseases are diagnosed and monitored using imaging. **You may be eligible if...** - You are 18 years of age or older - You have suspected, newly diagnosed, or previously treated Parkinson's disease or a related condition - You are already scheduled to have an alpha-synuclein PET/CT scan as part of your care - You (or your parent or legal representative) can provide written informed consent **You may NOT be eligible if...** - You do not have a Parkinson's-related condition - You are pregnant - You (or your legal representative) are unable or unwilling to provide written consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TEST18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06

Each subject receive a single intravenous injection of 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 and undergo PET/CT or MRI imaging within the specificed time.